SLC39A6 and breast carcinoma: We have additionally established that ZIP6/ZIP10 antibody treatment inhibits mitosis in triple negative breast cancer cell lines (Fig. 2), a form of breast cancer with poor treatment and prognosis, offering potential for a new treatment.